What the company does
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. It offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand. Its product pipeline includes KN026, an anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antibody (BsAb) that is in Phase III clinical trials to treat HER2-positive breast cancer and HER2-positive gastric cancer or gastroesophageal junction cancer; KN046, a BsAb immune checkpoint inhibitor …
What the weekly tape is saying
9966 closed the latest completed week at 7.10 HKD. The 4-week return is -20.4% and the 12-week return is -15.0%. Trend Signal is inactive, Market Dynamics is 0.01. Setup signature: Risk-first tape with a 20/100 composite read.
A compressed read of the whole setup
The radar blends trend persistence, momentum, Market Dynamics, Relative Strength, volume confirmation, and risk control into one weekly cockpit.
Scoreboard
16-week signal tape
Price, Trend Line, and Fair Value
Weekly price context with the latest close, trend position, Fair Value gap, drawdown, and 52-week range location.
52-week price path
Price map
- Trend Line
- 9.48 HKD
- Vs Trend Line
- -25.1%
- Fair Value
- 6.98 HKD
- Vs Fair Value
- 1.8%
- 52W High
- 15.75 HKD
- 52W Low
- 6.01 HKD
- Drawdown
- -54.9%
- Range Position
- 11.2%
Returns and trend persistence
Return windows separate the latest week from short-term and medium-term follow-through.
Return windows
Trend read
- Active Streak
- 0 weeks
- 52W Active Weeks
- 30
- 52W Active Breadth
- 57.7%
- Sector Scope
- HK Healthcare
- Sector Rank
- 56 of 257
- Sector Percentile
- 78.5%
Sector and industry pulse
Peer breadth helps separate a stock-specific move from a broader group rotation.
HK Healthcare
- Tracked Peers
- 100
- 4W Rank
- 82 of 100
- Avg 1W
- -1.3%
- Avg 4W
- -12.8%
- Trend Breadth
- 6.0%
- Positive MD
- 10.0%
HK Biotechnology
- Tracked Peers
- 76
- 4W Rank
- 45 of 76
- Avg 1W
- -1.6%
- Avg 4W
- -17.5%
- Trend Breadth
- 3.9%
- Positive RS
- 5.3%
Pressure, Relative Strength, and expectation
Market Dynamics and Relative Strength show whether buying pressure and relative leadership are confirming the price move.
Dynamics path
Signal state
- Market Dynamics
- 0.01
- 4W MD Change
- -98.6%
- Relative Strength
- -24.25
- 4W RS Change
- -141.9%
- Expectation
- Undecided
- Probability
- 47.57%
Participation and confirmation
Volume tells us whether the latest weekly move is being confirmed by unusual participation.
52-week volume profile
Volume map
- Latest Volume
- 10.4M
- 13W Average
- 9.3M
- 52W Average
- 12.5M
- Vs 13W
- 1.1x
- Vs 52W
- 0.8x
Volatility, downside weeks, and return shape
A compact risk profile shows whether the move is steady, volatile, or being driven by sharp one-week jumps.
26-week return distribution
Risk map
- 13W Volatility
- 12.1%
- 52W Volatility
- 11.2%
- Upside Weeks
- 25
- Downside Weeks
- 27
- Downside Breadth
- 51.9%
- Avg Gain / Loss
- 9.5% / -8.1%
Classification, opportunities, risks, and watch points
Top-level read across company classification, constructive evidence, caution points, and the next things that matter.
Classification
- Exchange
- HKG
- Country
- HK
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- HKD
- Market Cap
- 8.0B
Opportunity signals
- Price is above Fair Value, showing premium demand versus the model.
- Market Dynamics is positive on the latest completed week.
- Latest weekly return ranks in the strongest part of its sector group.
Risk signals
- Trend Signal is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- The share remains more than 20% below its 52-week high.
Watch next
- Trend Line remains the key weekly regime level.
- Market Dynamics is the pressure gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Recent completed weeks
The latest weekly rows behind the report snapshot.
| Week | Close | Return | Trend | Fair Value | MD | RS | Volume | Signal |
|---|---|---|---|---|---|---|---|---|
| 12 Jun 2026 | 7.10 HKD | 2.2% | 9.48 HKD | 6.98 HKD | 0.01 | -24.25 | 10.4M | Off |
| 5 Jun 2026 | 6.95 HKD | -23.6% | 9.57 HKD | 6.98 HKD | 0.20 | -26.75 | 21.2M | Off |
| 29 May 2026 | 9.10 HKD | -2.7% | 9.65 HKD | 6.99 HKD | 0.38 | -5.20 | 9.4M | Off |
| 22 May 2026 | 9.35 HKD | 4.8% | 9.73 HKD | 6.98 HKD | 0.45 | -4.32 | 6.5M | Off |
| 15 May 2026 | 8.92 HKD | -11.1% | 9.82 HKD | 6.98 HKD | 0.64 | -10.02 | 8.3M | Off |
| 8 May 2026 | 10.03 HKD | -2.6% | 10.00 HKD | 6.98 HKD | 0.88 | -0.20 | 5.3M | Off |
| 1 May 2026 | 10.30 HKD | -8.2% | 10.10 HKD | 7.01 HKD | 0.66 | 5.26 | 4.7M | Off |
| 24 Apr 2026 | 11.22 HKD | -5.7% | 10.27 HKD | 7.04 HKD | 0.45 | 14.06 | 8.8M | Off |
| 17 Apr 2026 | 11.90 HKD | 26.7% | 10.30 HKD | 7.06 HKD | -0.16 | 20.86 | 17.9M | Off |
| 10 Apr 2026 | 9.39 HKD | 3.9% | 10.30 HKD | 7.09 HKD | -0.83 | -2.93 | 4.1M | Off |
| 3 Apr 2026 | 9.04 HKD | 17.4% | 10.40 HKD | 7.13 HKD | -1.12 | -3.37 | 11.4M | Off |
| 27 Mar 2026 | 7.70 HKD | -7.8% | 10.44 HKD | 7.17 HKD | -1.40 | -17.09 | 6.9M | Off |
| 20 Mar 2026 | 8.35 HKD | -2.9% | 10.49 HKD | 7.21 HKD | -1.38 | -11.44 | 5.5M | Off |
| 13 Mar 2026 | 8.60 HKD | 9.6% | 10.57 HKD | 7.25 HKD | -1.37 | -9.38 | 5.3M | Off |